Sanofi India Ltd. Share Price

Overview

Sanofi India Ltd. share price is currently ₹3,100.96, up by ₹98.77 (3.29%) from its previous closing price of ₹3,002.19. The share price has declined -2.05% over the past month and declined -37.87% over the past year. The stock's 52-week low and high are ₹2,990.95 and ₹4,918.57, respectively. Sanofi India Ltd. has a market capitalisation of ₹ 7,110.00 Cr. The share price was last updated on 24 Sep 2026, 03:58 PM IST.

Sanofi India Ltd.
Sanofi India Ltd.
SANOFI
 0.00
 98.77
3.29%
Healthcare
 0.00(%)1D

Updated: 24 Sep 2026, 03:58:01 pm IST

Market Data

Open Price

 3,122.50

Prev. Close

 3,002.19
 3,075.92

Day Low

 3,148.88

Day High

 2,990.95

52 Week Low

 4,918.57

52 Week High

HealthcarePharmaceuticals & Drugs
CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

22.03

Sector PE

44.91

PB Ratio

10.53

Sector PB

5.97

EPS

140.78

Dividend Yield

3.01

Today's Volume

112.833 K

5 Day Avg. Volume

32.178 K

PEG Ratio

5.32

Market Cap.

₹ 7,110.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 480% at ₹48/Share
22-Apr-202622-Apr-2026
DividendsInterim Dividend of 750% at ₹75/Share
07-Nov-202507-Nov-2025
DividendsFinal Dividend of 1170% at ₹117/Share
25-Apr-202525-Apr-2025

Mutual Fund Ownership

Mutual Fund Holder
Jul 26
Shares held
Aug 26
Shares held
Nippon India Small Cap Fund - Growth4.80 Lac
4.80 Lac
no change
Aditya Birla Sun Life Large Cap Fund - Regular Plan - Growth3.40 Lac
3.40 Lac
no change
Nippon India Pharma Fund - Growth3.00 Lac
3.00 Lac
no change
SBI Contra Fund - Regular Plan - IDCW2.52 Lac
2.52 Lac
no change
Nippon India Growth Mid Cap Fund - Growth Option1.81 Lac
1.81 Lac
no change

About Sanofi India Ltd. 👋

Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
SASI KUMAR SEBI RA

SASI KUMAR SEBI RA

9 Sep • 8:13 AM · SEBI-Registered Analyst

Pre Market Report & Global Cues | 09 September

Global cues are weak this morning. US markets closed in the red. Dow fell 1.18%, S&P 0.58%, and Nasdaq 0.32%. The main reason is strong US job data (162K vs 53K expected), which has again increased the chances of a rate hike. Because of this, the US 10Y yield is holding near 4.79%, and that is keeping pressure on global markets. Crude oil is the bigger concern right now. Brent is close to $99.5 after fresh tensions in West Asia and issues around the Strait of Hormuz. For India, this is clearly negative as it affects inflation and keeps pressure on the rupee. There is also some global uncertainty after Canada imposed tariffs on US goods, which is adding to the cautious sentiment. Asian markets are mixed. Kospi is up around 1.6%, but Hang Seng and Straits Times are slightly weak. Because of this, Gift Nifty is indicating a flat to slightly positive start. On the domestic side, India 10Y yield is around 6.95%, which is still on the higher side. The rupee has weakened to 94.8, showing pressure due to rising crude. Nifty closed at 23,635 in the previous session and the overall trend still looks weak. Even if we open flat, the market needs strong buying to turn positive. One more thing to note: ADRs were weak: Infosys, Wipro, HDFC Bank and ICICI Bank all saw selling. So IT and banking stocks may start the day under pressure. There will be stock-specific action as well. On the positive side, Enviro Infra has won a ₹190 Cr order, TCS secured a government deal, and NLC India got a 200 MW wind project. Raymond is also in focus after approving a fund raise. On the negative side, Moschip may see pressure due to a legal issue, while Biocon and Sanofi India may remain volatile due to ongoing developments. Sector-wise: Oil-sensitive sectors like aviation, paints and tyres may remain under pressure due to high crude. IT stocks may stay weak after the ADR fall. Capital goods and infra may see stock-specific buying.

See More
Stock Reader

Stock Reader

7 Sep • 8:45 PM · SEBI-Registered Analyst

Cipla — The Respiratory Leader Is Building Its Next Engine

CIPLA
Respiratory is growing. Chronic therapies are expanding. India is scaling. And Cipla is steadily turning its strong domestic franchise into a broader healthcare growth story. Cipla is no longer just a traditional pharma company. It is becoming a diversified healthcare platform with strong brands, chronic therapies and differentiated products. The biggest trigger is India growth. Cipla's One-India business grew 9% in FY26, while its India prescription portfolio crossed ₹9,500 crore. Respiratory, diabetes and cardiac therapies remained key growth drivers.  And respiratory remains the crown jewel. Cipla holds a 26.2% market share in India's respiratory segment, with respiratory growth of 10.9%, while its flagship Foracort crossed the ₹1,000 crore milestone.  Then comes the real opportunity — chronic healthcare. Respiratory ↑ Diabetes ↑ Cardiac ↑ Urology ↑ Consumer Health ↑ Emerging Markets ↑ Cipla is also expanding beyond its established portfolio through partnerships with Eli Lilly, Novartis, Roche and Sanofi, while building exposure to diabetes, obesity, oncology and other high-growth therapies.  And the international business adds another layer. Cipla's FY26 emerging-market and European portfolio generated $780 million, while its US generics business maintained a top-20 position with a 1.57% market share. The company filed 10 products with the US FDA during FY26, including respiratory, peptide and complex-generic opportunities.  This is where the story becomes interesting: Strong brands → Chronic therapies → New launches → Higher mix → Better growth Cipla is also investing heavily in AI, digital capabilities and next-generation drug development — potentially improving productivity across R&D, manufacturing and patient engagement.  Of course, US pricing pressure, regulatory risks, generic competition and product concentration remain important risks. But the structural opportunity is powerful. Respiratory is strong. India is growing.

See More
VIJAY KUMAR GUPTA

VIJAY KUMAR GUPTA

23 Jun • 1:14 PM · SEBI-Registered Analyst

SHAILY
Shaily Engineering Plastics Ltd (commonly referred to as Shaily Ltd) is a premier Indian manufacturer and global exporter of high-precision injection-molded plastic components. Established in 1987, the company is headquartered in Vadodara, Gujarat, and operates several state-of-the-art manufacturing plants. It serves major global brands across highly demanding sectors like healthcare, consumer goods, personal care, and automotive ***** Business & OperationsHealthcare & Pharma Devices: Shaily operates as a Contract Development and Manufacturing Organization (CDMO). It manufactures complex drug delivery devices like insulin pens and oral solid/liquid primary packaging under cleanroom ***** Goods & Personal Care: The company supplies high-volume molded components and decorative cosmetic packaging for major multinational ***** Global Clients: Trusted by industry giants including IKEA, Procter & Gamble, Hindustan Unilever, Sanofi, Dr. Reddy's, Siemens, and ***** Scale: Features over 200 high-speed automated and robotic injection molding machines across plants in ***** Expertise: Recognized as the only licensed processor of Torlon (an ultra-high-performance polymer) in ***** & Stock OverviewAs of June 2026:Ticker Symbols: Listed on Indian stock exchanges as SHAILY (NSE) and 539794 (BSE).Market Capitalization: Approximately ₹12,700 Crore – ₹12,900 Crore, classifying it as a mid-to-micro cap public ***** Share Price: Trading around ₹2,800 to ₹2,820 per share.52-Week Range: Low of ₹1,535.90 to a High of ₹3,***** Metrics: Positioned at a high trailing Price-to-Earnings (P/E) ratio of ~75x to 80x, indicating strong premium valuation and high growth expectations from ***** Earnings Performance: Showed robust financial health in its March 2026 quarterly results, reporting a consolidated net profit growth of over 40% Year-on-Year (YoY) to roughly ₹40-49 Crore.

See More
saurabh mittal

saurabh mittal

17 Jun • 9:27 AM · SEBI-Registered Analyst

Cipla Ltd strengthened its play in beauty and personal care

CIPLA
expanding its consumer health business segment. Cipla announced additional investment in Achira, strengthening its strategic partnerships. Sanofi and Cipla announced an exclusive distribution partnership to expand reach of CNS portfolio in India, enhancing the company's presence in the specialty pharmaceutical market. Cipla strengthened its fight against antimicrobial resistance (AMR), securing approval to introduce ZEMDRI® (plazomicin) injection in India, demonstrating commitment to addressing critical healthcare challenges.

See More
Rakesh Kumar

Rakesh Kumar

13 May • 5:27 PM · SEBI-Registered Analyst

Emcure pharma Results Analysis-Q4FY26

EMCURE
Operating Revenue for Q4FY26 is Rs. 2,470 Crs., 16.7% growth YoY, Total Income is Rs. 2,474 Crs., 16.65% growth YoY, Gross Profit is Rs. 1,467 Crs., 19.81% growth YoY, EBITDA is Rs. 485 Crs., 24.5% growth YoY, EBITDA Margin is 19.66% improved by 123 Basis points YoY (EBITDA margins improved despite increased R&D investment, supported by higher gross profit margin), PBT Rs. 341 Crs. 30.92% growth YoY, PAT Rs. 244 Crs. 23.58% growth YoY. Robust International Markets performance (revenue up 25.7% YoY); contribution at 60%. On QoQ basis Op. Revenue is up by 4.49%, Total Income is up by 4.58%, Gross Profit is up by 4.68%, EBITDA is up by 5.51%,, PBT is up by 8.73% and PAT is also up by 5.35%. Strategic portfolio expansion : Partnership with Novo Nordisk for Poviztra, expansion of Sanofi partnership for oral anti-diabetic portfolio (Amaryl & Cetapin); Roche partnership for nephrology and transplant products Full consolidation of Zuventus through minority stake buyout Manx and Cutimed acquisitions in Europe and Canada, respectively.

See More
Prameela Balakkala

Prameela Balakkala

29 Apr • 8:34 AM · SEBI-Registered Analyst

Sanofi India Q4 FY26: Profit & Revenue Decline, Margins Under Pressure

SANOFI
📊 Financial Performance Net Profit: ₹1B vs ₹1.2B YoY (↓17%). Revenue: ₹4.7B vs ₹5.4B YoY (↓13%). EBITDA: ₹1.4B vs ₹1.7B YoY (↓18%). EBITDA Margin: 30.24% vs 32.08% YoY (margin contraction). 📈 Key Financial Ratios Net Profit Margin: ~21.3% (down from ~22.2% YoY). EBITDA Margin: 30.2% (down from 32.1%). ROE: ~12–13% (moderate, impacted by profit decline). ROCE: ~11–12% (reflects weaker capital efficiency). Debt-to-Equity: Very low, Sanofi India operates with a strong balance sheet. Interest Coverage Ratio: High, minimal debt burden. ✅ Fundamentals Global Pharma Backing: Strong parentage under Sanofi Group ensures R&D and product pipeline support. Profitability: Despite decline, margins remain healthy above 30%. Cash Flow Strength: Low leverage and strong liquidity. Product Portfolio: Focus on vaccines, diabetes care, and specialty medicines. Dividend Policy: Historically consistent, though not announced this quarter. ⚠️ Risks & Challenges Revenue Decline: Lower sales impacted by pricing pressure and competition. Margin Contraction: Rising input and compliance costs. Regulatory Risks: Pharma sector faces strict norms on pricing and approvals. Competition: Intense rivalry from domestic and multinational pharma companies. Patent & Pipeline Risks: Dependence on new launches and regulatory clearances.

See More

Frequently Asked Questions

What is the share price of Sanofi India Ltd.?

What is the market cap of Sanofi India Ltd.?

Should I buy Sanofi India Ltd. stock now?

What is the 52 week high and low of Sanofi India Ltd.?

Is the Sanofi India Ltd. stock good to buy?

Is Sanofi India Ltd. a good buy for the long term?

Is Sanofi India Ltd. overvalued or undervalued?

What is the PE and PB ratio of Sanofi India Ltd.?

Start Now